论文部分内容阅读
目的：对89Sr治疗骨转移癌患者的临床效果进行评价。方法研究对象为我科收治的60例骨转移癌患者,均行89Sr治疗,总治疗次数为76次,每例患者每次89Sr计量为4mci。分别于治疗前和治疗后3个月对患者实施全身骨显像检查,记录患者骨痛消失、开始缓解、缓解持续和复发时间。结果全身骨显像检查显示,患者病灶数目明显减少、病灶范围缩小,病灶放射性计数减少,临床治疗总有效率为87%,药物不良反应发生率为35%,患者主观骨痛反应玉级率为53.3%,Ⅱ级率为33.3%,与治疗前比较差异具有统计学意义(<0.05)。结论89Sr治疗骨转移癌,疗效确切,安全性高。“,”Objective To evaluate the clinical ef ect of 89Sr in the treatment of patients with bone metastases. Methods Selected 60 cases of patients with bone metastasis in our department. The total number of patients treated with 89Sr was 76 times, and the number of patients with 89Sr was 4mci. Before and after 3 months in patients with implementation of whole body bone imaging, recorded the time of bone pain disappeared, began to ease, sustained remission and relapse. Results As whole body bone imaging examination showed, which significantly reduced the number of patients with lesions, nar ow the scope of lesions and lesions radioactive counts, the clinical treatment of total ef iciency was 87%, and the adverse drug reactions occur ed rate was 35%. The patients subjective pain reaction I grade rate was 53.3%, grade II rate was 33.3%, which has statistical significance as compared with that before treatment ( < 0.05). Conclusion 89Sr in the treatment of bone metastasis cancer has good curative ef ect and is safe.